Anteris Technologies (ASX:AVR) said clinical outcomes for its transcatheter heart valve DurAVR in 100 severe aortic stenosis patients with small aortic annuli showed no moderate or severe paravalvular leaks and no valve-related mortality, according to a Monday filing with the Australian bourse.

The results also showed 97% freedom from moderate or severe prosthesis-patient mismatch (PPM) in a group of small annuli patients, the filing said.

Moderate to severe PPM is independently associated with reduced survival and increased risk of structural valve deterioration, the filing added.

Shares of the company fell 2% in recent Monday trade.